1. Home
  2. ADCT vs LWLG Comparison

ADCT vs LWLG Comparison

Compare ADCT & LWLG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADCT
  • LWLG
  • Stock Information
  • Founded
  • ADCT 2011
  • LWLG 1991
  • Country
  • ADCT Switzerland
  • LWLG United States
  • Employees
  • ADCT N/A
  • LWLG N/A
  • Industry
  • ADCT Biotechnology: Pharmaceutical Preparations
  • LWLG Containers/Packaging
  • Sector
  • ADCT Health Care
  • LWLG Industrials
  • Exchange
  • ADCT Nasdaq
  • LWLG Nasdaq
  • Market Cap
  • ADCT 398.2M
  • LWLG 423.3M
  • IPO Year
  • ADCT 2020
  • LWLG N/A
  • Fundamental
  • Price
  • ADCT $3.25
  • LWLG $3.01
  • Analyst Decision
  • ADCT Strong Buy
  • LWLG
  • Analyst Count
  • ADCT 6
  • LWLG 0
  • Target Price
  • ADCT $7.80
  • LWLG N/A
  • AVG Volume (30 Days)
  • ADCT 545.2K
  • LWLG 2.5M
  • Earning Date
  • ADCT 11-06-2025
  • LWLG 11-12-2025
  • Dividend Yield
  • ADCT N/A
  • LWLG N/A
  • EPS Growth
  • ADCT N/A
  • LWLG N/A
  • EPS
  • ADCT N/A
  • LWLG N/A
  • Revenue
  • ADCT $77,246,000.00
  • LWLG $94,355.00
  • Revenue This Year
  • ADCT $13.10
  • LWLG N/A
  • Revenue Next Year
  • ADCT $6.23
  • LWLG N/A
  • P/E Ratio
  • ADCT N/A
  • LWLG N/A
  • Revenue Growth
  • ADCT 15.73
  • LWLG 4.52
  • 52 Week Low
  • ADCT $1.05
  • LWLG $0.79
  • 52 Week High
  • ADCT $3.97
  • LWLG $4.23
  • Technical
  • Relative Strength Index (RSI)
  • ADCT 51.93
  • LWLG 66.58
  • Support Level
  • ADCT $3.15
  • LWLG $2.84
  • Resistance Level
  • ADCT $3.38
  • LWLG $3.42
  • Average True Range (ATR)
  • ADCT 0.18
  • LWLG 0.35
  • MACD
  • ADCT -0.02
  • LWLG -0.01
  • Stochastic Oscillator
  • ADCT 38.53
  • LWLG 87.91

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

About LWLG Lightwave Logic Inc.

Lightwave Logic Inc is a United States-based development stage company moving toward commercialization of next-generation electro-optic photonic devices made on its P2IC technology platform which uses in-house proprietary high-activity and high-stability organic polymers. Electro-optical devices convert data from electric signals into optical signals for multiple applications. It designs and synthesizes organic chromophores for use in its own proprietary electro-optic polymer systems and photonic device designs.

Share on Social Networks: